Stockreport

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech, Inc.  (IOBT) 
PDF Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across [Read more]